Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
Zhuoming Liu, Hua Wu, Kristi A. Egland, Theron C. Gilliland, Matthew D. Dunn, Thomas Luke, Eddie J. Sullivan, William B. Klimstra, Christoph Bausch, Sean P. J. Whelan
Abstract
. Neutralization potency was retained for S variants including S477N, E484K, and N501Y, substitutions present in recent variants of concern. In contrast to the ease of selection of escape variants with mAbs and convalescent human plasma, we were unable to isolate VSV-SARS-CoV-2 mutants resistant to Tc-hIgG-SARS-CoV-2 neutralization. This fully human immunoglobulin that potently inhibits SARS-CoV-2 infection may provide an effective therapeutic to combat COVID-19.
Topics & Concepts
VirologyNeutralizationPolyclonal antibodiesAntibodyBiologyMonoclonal antibodyVesicular stomatitis virusAntigenNeutralizing antibodyImmunoglobulin GCoronavirusImmunizationVirusImmunologyMedicineCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesVirus-based gene therapy research